Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 12/20 | 0.55 |
| ▸ | EDNRB | P24530 | 11/20 | 0.55 |
| ▸ | DHPS | P49366 | 8/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5631703 | 0.87 | EDNRA (0.54) | EDNRAEDNRBDHPS | |
| SCHEMBL5633509 | 0.86 | EDNRA (0.54) | EDNRAEDNRBDHPS | |
| SCHEMBL7868568 | 0.85 | EDNRA (0.58) | EDNRAEDNRBDHPS | |
| SCHEMBL5499789 | 0.85 | EDNRA (0.63) | EDNRAEDNRBDHPS | |
| SCHEMBL14380614 | 0.84 | EDNRA (0.51) | EDNRAEDNRBDHPS | |
| SCHEMBL7839633 | 0.83 | EDNRA (0.50) | EDNRAEDNRBDHPS | |
| SCHEMBL7839629 | 0.83 | EDNRA (0.50) | EDNRAEDNRBDHPS | |
| SCHEMBL14380584 | 0.83 | EDNRA (0.67) | EDNRAEDNRBDHPS | |
| SCHEMBL5633038 | 0.83 | EDNRA (0.61) | EDNRAEDNRBDHPS | |
| SCHEMBL6786069 | 0.83 | EDNRA (0.82) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285549-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-23 | — | — | US | disclosed |
| US-7094781-B2 | Sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-22 | — | — | US | disclosed |
| US-20060178365-A1 | Optionally oxidized 6-(2-(5-methylthio-2-pyrimidinyloxy)ethoxy)-2-phenylpyrimidin-4-yl-substituted sulfamides | BOLLI MARTIN | 2006-08-10 | — | — | US | disclosed |
| EP-1345920-B1 | NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-04-12 | — | — | EP | disclosed |
| US-20040077670-A1 | Novel sulfamides and their use as endothelin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178365-A1 | Optionally oxidized 6-(2-(5-methylthio-2-pyrimidinyloxy)ethoxy)-2-phenylpyrimidin-4-yl-substituted sulfamides | EDNRA, EDNRB, ECE2 | EDNRA 1/4885EDNRB 2/4885DHPS 273/4885 |
| US-20040077670-A1 | Novel sulfamides and their use as endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | EDNRA 1/4885EDNRB 2/4885DHPS 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.